Cite
MLA Citation
Timothy Price et al.. “403 Early results from a phase 1 study to evaluate safety, pharmacokinetics, and efficacy of AMG 404, a programmed death-1 (PD-1) antibody, in patients with advanced solid tumors.” Journal for immunotherapy of cancer, vol. 8, n.d., p. A245. http://access.bl.uk/ark:/81055/vdc_100144725230.0x000005